Cargando…

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung

BACKGROUND: With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janzic, Urska, Kern, Izidor, Janzic, Andrej, Cavka, Luka, Cufer, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter Open 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612001/ https://www.ncbi.nlm.nih.gov/pubmed/28959173 http://dx.doi.org/10.1515/raon-2017-0037

Ejemplares similares

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
por: Stanic, Karmen, et al.
Publicado: (2014)

Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival
por: Humar, Mojca, et al.
Publicado: (2017)

BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma
por: Koren, Ana, et al.
Publicado: (2016)

Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer
por: Koren, Ana, et al.
Publicado: (2021)

High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients
por: Koren, Ana, et al.
Publicado: (2017)

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
por: Detiček, Andreja, et al.
Publicado: (2018)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Real-life Long-term Outcomes of Upfront Surgery in Patients with Resectable Stage I-IIIA Non-small Cell Lung Cancer
por: Bitenc, Marko, et al.
Publicado: (2022)

Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
por: Heeren, A Marijne, et al.
Publicado: (2016)

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
por: Ljubicic, Lidija, et al.
Publicado: (2023)

Real-world Outcomes, Treatment Patterns and T790M Testing Rates in Non-small Cell Lung Cancer Patients Treated with First-line First- or Second-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors from the Slovenian Cohort of the REFLECT Study
por: Turnsek, Nina, et al.
Publicado: (2022)

Various Clinical Presentations of Uveitis Associated with Durvalumab Treatment
por: Vrabic, Nika, et al.
Publicado: (2022)

1615P Impact of the COVID-19 pandemic on diagnosing and treatment referrals of lung cancer patients: A single-centre experience
por: Janzic, U., et al.
Publicado: (2021)

Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)
por: Janžič, Urška, et al.
Publicado: (2022)

A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
por: Janzic, Urska, et al.
Publicado: (2023)

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
por: Janzic, Urska, et al.
Publicado: (2023)

Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists
por: Brcic, Luka, et al.
Publicado: (2020)

The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
por: Chen, Lu, et al.
Publicado: (2019)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
por: Ma, Ke, et al.
Publicado: (2020)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2022)

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
por: Porcellato, Ilaria, et al.
Publicado: (2021)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
por: Janzic, Urska, et al.
Publicado: (2022)

Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
por: Tokuyasu, Hirokazu, et al.
Publicado: (2019)

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
por: Foy, Jean-Philippe, et al.
Publicado: (2022)

Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series
por: Fernández-Trujillo, Liliana, et al.
Publicado: (2020)

Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung
por: Tashima, Yuko, et al.
Publicado: (2020)

PD-1/PD-L1 expression in anal squamous intraepithelial lesions
por: Bucau, Margot, et al.
Publicado: (2020)

PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
por: Okadome, Kazuo, et al.
Publicado: (2021)

Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
por: Yoon, Jiyoung, et al.
Publicado: (2020)

Clinical importance of VEGFC and PD‐L1 co‐expression in lung adenocarcinoma patients
por: Qin, Tingting, et al.
Publicado: (2020)

BIRC5 Modulates PD-L1 Expression and Immune Infiltration in Lung Adenocarcinoma
por: Ma, Teng, et al.
Publicado: (2022)

PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma
por: Tojyo, Itaru, et al.
Publicado: (2019)

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
por: Cavka, Luka, et al.
Publicado: (2021)

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
por: Rasmussen, Jacob H., et al.
Publicado: (2019)

Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
por: Wessely, Anja, et al.
Publicado: (2020)

Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
por: Blatt, Sebastian, et al.
Publicado: (2022)

Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
por: Weber, Manuel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o5n3dnio1n8p117djn9a91667c